Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Clinical study on the second-line treatment of advanced esophageal squamous cell carcinoma with camrelizumab combined with apatinib and irinotecan: A single-arm, multicenter, phase II study.
Authors
Yifu He
Department of Oncology, The First Affiliated Hospital of USTC West District, Hefei, China
Yifu He , Chenghui Li , Fenglin Zhang , Bing Hu , Yubei Sun , Xiaoyang Xia , Yanshun Zhang , Gang Wang , Tengyun Xu , Aixiong Duan , Shusheng Wu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
ChiCTR2000028857
DOI
10.1200/JCO.2022.40.4_suppl.319
Abstract #
319
Poster Bd #
L7
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Camrelizumab in combination with apatinib as second-line treatment for advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study.
First Author: Feng Wang
Poster
2023 ASCO Annual Meeting
A phase Ib/II study to evaluate surufatinib combined with camrelizumab and chemotherapy in the second-line treatment of advanced colorectal cancer: Phase Ib results.
First Author: Sheng Li
Poster
2022 ASCO Annual Meeting
A phase II study to evaluate the safety and efficacy of radiotherapy combined with irinotecan liposome followed by camrelizumab and apatinib for advanced solid tumors that failed standard treatments.
First Author: Jie Shen
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Real-world effectiveness of anlotinib in combination with PD-1 inhibitors as second-line or later therapy for advanced or metastatic esophageal squamous cell carcinoma.
First Author: Yonggui Hong